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Abstract Procalcitonin (PCT), a 116-aminoacids prohormone,
has been substantially studied over the last 2 decades in the field
of sepsis. Disappointingly low sensitivity values led to the
abandonment of the concept of it as a diagnostic tool and then
to its being considered more as a prognostic marker with a good
correlation with severe infection. Later on, growing concerns
about multidrug-resistant bacteria in the ICU environment and
about the cost and side effects of antibiotics suggested that PCT
might prove to be a valuable asset in stewardship programs.
Numerous but hardly comparable randomized controlled trials
assessing either initiation or deescalation in ICU patients have
been published. Stewardship encompassing PCT should focus
on the latter, because of the high negative predictive value of this
biomarker. However, there still would be safety concerns if a
systematic implementation of PCT were to be considered in
daily stewardship programs in the ICU, especially in extra-
thoracic sepsis.
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Introduction
Since its first description in children and burned patients 2
decades ago [1], procalcitonin (PCT) has traveled a long way
from diagnosis of infectious chronic obstructive pulmonary
disease (COPD) exacerbation in the emergency department to
its current concept as a possible tool for antibiotic stewardship
in our busier intensive care units (ICUs) with worsening eco-
logical environments [2, 3] (Fig. 1). Indeed, it was first thought
to be helpful in the discrimination between severe infection and
nonspecific hyperinflammatory states [4•]. Intensive care phy-
sicians are daily challenged with the risk of initiating useless
and potentially toxic (for the patient and the environment)
treatments in the absence of specific clinical signs and of a
gold-standard biomarker in the field of sepsis. PCTwas histor-
ically studied in various settings and clinical conditions, includ-
ing emergency departments, neonatal sepsis, and ICU patients
[5, 6]. However, unacceptably low sensitivity values in the
setting of critically ill patients, ranging from 67 % to 80 %
depending on the chosen cutoff [7, 8, 9•, 10•], led to its being
considered rather as a prognostic tool in terms of severity of
illness and outcome. In that sense, PCT met the fate of other
acute phase reactants that did not show satisfactory specificity.
PCT is notoriously raised, in the absence of infection, in
pancreatitis, ischemic bowel disease, cardiopulmonary bypass,
and metastatic disease [11] and with the intake of some drugs
(monoclonal antibodies, antithymocyte globulin, etc.) [12••,
13]. PCT does not rise incases of local bacterial, viral, parasitic,
or fungal infection. Between 2006 and 2008, numerous studies
involving very different types of patients (medical vs. surgical,
immunocompetent vs. immunocompromised) and indications
(severe community-acquired pneumonia, sepsis) [14, 15] were
undertaken. Some studies focused strictly on prognostic signif-
icance, whereas others combined the diagnostic and prognostic
abilities of the test. Interestingly, PCT was combined with
others biomarkers (CRP, sTREM-1, SUPAR, TNF-alpha, IL-
6, IL-8), clinical scoring systems (SAPSII), and biological
markers of sepsis such as lactate [16–18]. The results were
better in the multimodal approach, as opposed to the use of
PCT alone, for determination of outcome (AUC 0.72–0.88). It
is now commonly admitted that higher values (1.5–over 5 μg/l)
in high-risk patients are correlated with bacterial load and
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bacteremia [19], severity of organ failure [20, 21], and, in some
studies, mortality [6, 22].
Core Text
After an initial encouraging report on the usefulness of PCT
for safe reduction of antibiotic therapy in lower respiratory
tract infections (RTIs) in 2004 [23, 24], it was not until 2008
that the concept of PCT as a possible antibiotic stewardship
tool emerged in clinical studies involving ICU patients [25••]
(Table 1). The growing pressure of multidrug-resistant bacte-
ria in the ICU environment, combined with considerations
regarding cost and limitation of drug toxicity and interactions
[26, 27], offered the perfect opportunity for a new appraisal of
this biomarker, which had somehow failed to fulfill its prom-
ises. It is considered to be useful because of favorable kinetics
[28] and a high negative predictive value [17, 29–31].
Antibiotic stewardship encompassing PCT can be regarded
as a lack of initiation of antibiotics in the absence of bacterial
infection, thus calling into question the sensitivity of the bio-
marker, versus rapid stopping of them, in cases of a decrease of
PCT, on the basis of a daily check, either because clinical cure
is achieved or because infection has been safely ruled out.
Now, the first strategy encounters two hurdles. First, it
obviously does not fit into clinical practice dealing with seri-
ously ill patients, since protocol-overruling reports range from
20 % to 65 % [30, 32•, 33, 34]. In the Layios study, in 43/80
patients (belonging to the PCT arm, which comprised 258
patients) who had a PCT <0.25 μg/l, the diagnosis was
overruled by the treating physician, and they received antibi-
otics. Of note, 69.8 % of these treatments (30/43) were a
posteriori confirmed by the infectious diseases specialist to
have been appropriately initiated. Second, poor diagnostic
sensitivity was once again confirmed recently (AUC 0.69),
and two recent studies showed that the strategy is a failure in
an escalating or initiation process [10•, 30].
The second strategy, however, is supported by the physio-
logical decline within 48 h in noninfected patients [35, 36] and
has recently been shown to be cost effective, thanks to a 2-day
decrease in antibiotic consumption, although not altogether
convincingly safe [32•, 37]. The same degree of concern about
a possible excess of mortality had been raised in the
PRORATA study [33], and the debate is ongoing. Prior to
2010, five randomized controlled trials (RCTs) evaluating
deescalation in critically ill patients had shown reduction in
antibiotic consumption, without excess of morbidity or mor-
tality [38]. Interestingly, the same authors put into perspective
the fact that in nondocumented sepsis, the optimal duration of
antibacterial therapy is not known. Several other studies have
been published since then, reporting the same proportion of
safe antibiotic-free days (2–4 days) [31, 39•, 40], but only two
focused merely on severe extra-thoracic sepsis. The ESICM
meta-analysis reviewed seven RCTs in critically ill patients
and confirmed the safety of shortening antibiotic administra-
tion by just over 3 days, in terms of a similar rate of superin-
fections and recurrence of infection in the PCT-guided arm. A
consistent reduction of antibiotic therapy was also reported in
the review published by Schuetz et al. [41••], mainly owing to
shorter courses of antibiotic therapy (and not withholding of
initiation) amongmoderate- and high-acuity care patients. The
Schuetz study mixed lower RTIs and severe sepsis and septic
shock without further definition. The proposed PCT cutoff
values in the deescalating strategy in the ICUwere roughly the
same throughout all the recently published trials and meta-
analyses, meaning a drop of 80 %–90 % from the peak value
or a return to a level less than 0.25–1 μg/l in patients showing
clinical signs of recovery. Mortality has not been significantly
affected by that strategy in any of the trials published so far.
Importantly, PCT was extensively studied in the setting of














































































Fig. 1 Number of procalcitonin
publications including adult ICU
trials
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lower RTIs namely, ventilator-acquired pneumonia (VAP) in
immunocompetent adults—while severe sepsis (i.e., a syn-
drome defined as the host’s systemic inflammatory response
syndrome [SIRS] to infection) was the second cause of inclu-
sion of patients. However, the source and/or the microbiolog-
ical proof of infection have seldom been reported. This is very
intriguing after almost 2 decades of striving—and with, some-
times, rigorous research—to establish the utility of a bio-
marker in less rigorous conditions. It is also, in our view, the
biggest difficulty to overcome, since modern intensive care
is becoming, alas, more and more syndromic. Of interest,
the recently published and prematurely stopped study of
Annane et al. [42] failed to include patients because 80.6 %
of the eligible patients had a documented source of infec-
tion within 48 h of recognition of SIRS (before randomiza-
tion), 77.6 % of whom had a documented pathogen. Now
this was considered to be a major design flaw, but one
definitely has to put into perspective the utility of a bio-
marker when modern pathogen identification techniques
and experienced clinical judgment are combined. This
point is very interestingly raised by Póvoa et al. [43], who
reminded us of two studies, going 10 years back, that had
shown the effectiveness of a shorter (6–8 days) duration of
antibiotic therapy to be equal to that of a long-term course
(10–21 days) in VAP, but without the use of any biomarker.
Hence, the decision to recommend PCT’s usage in the
recent guidelines for deescalation in lower RTIs even in
the case of septic shock [44] leaves us skeptical. Proposals
and recommendations for the use of PCT in a strategy
aiming at antibiotic stewardship were issued by Schuetz
et al. [41••] and Foushee et al. in 2012 [12••], each in
distinct environments (Europe vs. Northern America, pri-
mary setting vs. low-, intermediate-, and high-risk pa-
tients), recommending caution regarding their implementa-
tion in immunocompromised and unstable patients. This is
in line with most studies focusing on the need for supple-
mentary data in favor of safe antibiotic stewardship, always
encompassing PCT in a multimodal approach. A prospec-
tive upcoming and well-enrolled study (the SAPS study),
the largest to be conducted so far in ICU patients, will
perhaps be able to answer questions about the cost, safety,
and effectiveness of such a strategy [45].
However, although convincing from the physiopathologi-
cal and, sometimes, evidence-based point of view, PCT’s
systematical implementation as a prognostic tool or, for ther-
apeutic monitoring, as a clinical algorithm for ICU patients
has not been widely encouraged so far.
Conclusion
PCT as an antibiotic stewardship tool aiming at appropriately
initiating antibiotics—that is, only in the setting of severe
infection—has recently once again proven to be futile, if not
detrimental. The 2013 surviving sepsis campaign (SSC)
guidelines propose PCT as a diagnostic aid, in conjunction
with the usual clinical signs, provided its value is superior
to 2 standard deviations above the normal value. This is,
in our opinion, a surrogate marker for poor sensitivity, and
it would have been more prudent not to include it at all in
the diagnostic strategy. Now, interest in PCT’s ability to
contribute to infected critically ill patients’ diagnosis and
prognosis has not worn out, as large-scale ongoing clinical
studies attest (accessed on clinicaltrials.gov on May 13,
2013), but we are doubtful about their ultimate daily
clinical implementation, given the amount of literature
already available and the understandable reluctance of the
intensive care physician, facing the possibility of uncon-
trolled sepsis, not to initiate antibiotics.
Hence, PCT as a therapeutic monitoring tool has looked
like an attractive alternative in view of its high negative
predictive value, but conclusive data concerning safety of
this strategy are still lacking, at least in extra-thoracic
severe sepsis. Concerning VAP, past studies have shown
efficacious and safe shorter duration of antibiotic therapy
without the need for a biomarker. Low adherence to pro-
tocol, even in the setting of controlled infection, is another
hurdle to its implementation in daily clinical practice, since
reports of overruling range from 16 % to 65 % [32•, 43].
Only a grade 2C level of recommendation was attributed to
PCT in the recently updated SSC guidelines when
deescalation was considered. Rather, narrowing of the spec-
trum of antibiotics or stopping is left to “clinical judgment
and information.”
On the other hand, high-throughput molecular techniques
such as multiplexed PCR and mass spectrometry allow more
rapid and less empiric pathogen identification nowadays [46].
These techniques should be evaluated in terms of cost effec-
tiveness, sensitivity, and specificity as part of a multimodal
stewardship program in the ICU that could encompass
bioscores such as the one recently described by Gibot et al.
[47•]. This approach would thus imply a patient-tailored treat-
ment based on individual phenotypic characteristics, com-
bined with a biomarker allowing prompt stopping of antibi-
otics in the absence of infection or, even better, consensus on
the optimal duration of therapy in sepsis without bacterial
documentation.
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